|
Year End Review Plus Manufacturer (CMO) Updates Edmonton, Alberta, December 7, 2007 CYPL: OTCBB, Frankfurt Exchange WKN:XYIA “Research and development on our recombinant protein Cyplasin-SC™ has been moved forward at a steady and strong pace over the last year,” states Garth Likes, President and CEO of Cyplasin. The development of Cyplasin-SC was started in early March 2007 and since that time the following product development milestones were achieved:
With respect to the manufacturing strategy; of the four original companies selected to submit quotes coming from countries from all around the world, two have been selected which Cyplasin Biomedical feels would best fit a successful completion of the tasks required. These two remaining contract manufacturing organizations (CMOs) both with certified GMP- facilities, will now enter into next stage negotiations with Cyplasin Biomedical Ltd, with a final decision as to which CMO will manufacture for Cyplasin Biomedical being taken before the end of next month. On a corporate development level Cyplasin Biomedical saw the launch of a new web site and the issuance of a second USA patent covering expanded claims for the manufacture and production of the recombinant protein Cyplasin-SC™. The Company also saw continued support from its investors and public markets as Cyplasin Biomedical executed on its R&D and corporate development programs resulting in strong shareholder value increases as reflected within its share price. "We expect to be able to continue this strong level of progress as Company plans for next year include conclusion of discussions with a CMO for production of Cyplasin, obtaining second efficacy validation in animals, initiation of an FDA preclinical meeting leading to final toxicology studies and an eventual filing of an IND allowing us to initiate human phase I clinical studies," explained Professor Petzelt Cyplasin’s CSO. Cyplasin-SC is being developed for use as an anticancer therapeutic drug for melanoma and skin cancer. About Melanoma Around 160,000 new cases of new melanoma cases are diagnosed worldwide each year. Melanoma is more frequently found in Caucasian males and is more common in Caucasian populations living in sunny climates than in other groups. Market statistics for skin cancer and melanoma show that melanoma currently affects more then 2.4 million people worldwide with 62,000 new cases being reported in the USA every year. Australia has the highest rate of melanoma in the world among males and has the second highest rate in the world among females (Australia’s Health 2004, AIHW). According to the WHO Report the world wide incidence has doubled over the past 20 years with about 48,000 melanoma related deaths occurring worldwide per annum. About Cyplasin-SC™ Cyplasin-SC™ has demonstrated a selective ability to rapidly kill certain types of cancer cells while leaving normal non-cancerous cells untouched. Cyplasin-SC is a protein originally discovered and isolated by Professor Petzelt from a marine organism, the sea hare (Aplysia punctata). The protein can now be manufactured as a recombinant protein which allows the company to develop the protein as an anti-cancer therapeutic product. Patents have been issued to the Company covering the Cyplasin-SC protein. About Cyplasin Biomedical Ltd. (CBL) Founded in 2007 and headquartered in Edmonton, Canada with a research laboratory close to Berlin, Germany, CBL is dedicated to bringing new anticancer therapeutics to the marketplace. The Company’s current goal is to develop and commercialize the anticancer properties of Cyplasin-SC™ against skin cancer and melanoma. CBL is publicly traded (CYPL: OTCBB) Forward-Looking Statements This Press release includes and is based, inter alia, on forward-looking information and statements that are subject to risks and uncertainties that could cause actual results to differ. Such forward-looking information and statements are based without limitation, as statements regarding future drug development activities, anticipated products, or anticipated future revenues, benefits or advantages, and the future plans and objectives of the Company, that involve inherent risks and uncertainties and are subject to factors, many of which are beyond the Company's control, such as market acceptance of new products and services, changes in governmental regulations, interest rates, fluctuations in currency exchange rates and such other factors as may be discussed from time to time that may cause actual results or performance to differ materially from those currently anticipated in such statements. These expectations, estimates and projections are generally identifiable by statements containing words such as "expects", "believes", "estimates" or similar expressions. Although Cyplasin Biomedical Ltd., believes that its expectations and the information in this Press release were based upon reasonable assumptions at the time when they were made, it can give no assurance that those expectations will be achieved or that the actual results will be as set out in this Press release. Cyplasin Biomedical Ltd., makes no representation or warranty, expressed or implied, as to the accuracy, reliability or completeness of the information in the Press release, and neither Cyplasin Biomedical nor any of their directors, officers or employees will have any liability to you or any other persons resulting from your use of the information in the Press release. The OTCBB Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this news release. Contact:
|